BriaCell Therapeutics (TSX:BCT) YoY EBITDA Growth: 94.22% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:BCT BriaCell Therapeutics Corp TSX:BCT
29 GF Score
Price C$4.98
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics YoY EBITDA Growth?

BriaCell Therapeutics TSX:BCT +1.22% 29 YoY EBITDA Growth is 94.22% as of Apr. 2026. GuruFocus rates TSX:BCT with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. BriaCell Therapeutics's YoY EBITDA Growth for the quarter that ended in Apr. 2026 was 94.22%.

BriaCell Therapeutics's EBITDA per Share for the three months ended in Apr. 2026 was C$-1.36.

BriaCell Therapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics YoY EBITDA Growth Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.48 43.24 20.68 77.03 -44.96

BriaCell Therapeutics Quarterly Data
Jan21 Apr21 Oct21 Jan22 Apr22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -208.57 55.72 86.38 89.16 94.22
TSX:BCT
29GF Score
BriaCell Therapeutics Corp TSX:BCT
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

BriaCell Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Jul. 2025 is calculated as:

YoY EBITDA Growth (A: Jul. 2025 )
=(EBITDA per Share (A: Jul. 2025 )-EBITDA per Share (A: Jul. 2024 ))/ | EBITDA per Share (A: Jul. 2024 ) |
=(-87.061--60.058)/ | -60.058 |
=-44.96 %

BriaCell Therapeutics's YoY EBITDA Growth for the quarter that ended in Apr. 2026 is calculated as:

YoY EBITDA Growth (Q: Apr. 2026 )
=(EBITDA per Share (Q: Apr. 2026 )-EBITDA per Share (Q: Apr. 2025 )) / | EBITDA per Share (Q: Apr. 2025 )) |
=(-1.356--23.45)/ | -23.45 |
=94.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 94.22% mean?
BriaCell Therapeutics (TSX:BCT) has a YoY EBITDA Growth of 94.22% as of Apr. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for BriaCell Therapeutics and its competitors.
Is BriaCell Therapeutics' YoY EBITDA Growth too high?
BriaCell Therapeutics' current YoY EBITDA Growth is 94.22%. Overall, BriaCell Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' YoY EBITDA Growth compare to VRTX and REGN?
BriaCell Therapeutics' YoY EBITDA Growth of 94.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for BriaCell Therapeutics and its competitors. BriaCell Therapeutics's current YoY EBITDA Growth is 94.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (TSX:BCT) has a current YoY EBITDA Growth of 94.22%. The current YoY EBITDA Growth is 94.22%. BriaCell Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For BriaCell Therapeutics (TSX:BCT), the current YoY EBITDA Growth is 94.22% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BriaCell Therapeutics Business Description

Other Exchanges BCTX:USA8BT:Germany
Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
29GF Score

Get the complete analysis for TSX:BCT

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.98
Price